3-(2,2,2-trimethylhydrazine)propionate has been researched along with Cardiovascular Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bode, LM; Eggers, M; Jahn, D; Jasper, J; Lubitz, W; Moser, J; Neubauer, K; Piskol, F; Reijerse, E; Slusarenko, A | 1 |
| Ageev, FT; Konovalova, GN; Kuzmina, AE; Lankin, VZ; Smirnova, MD; Svirida, ON; Tikhaze, AK; Vitsenia, MV | 1 |
| Ageev, FT; Forfanova, TV; Mikhaĭlov, GV; Smirnova, MD; Svirida, ON; Vitsenia, MV | 1 |
| Dambrova, M; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Vilskersts, R | 1 |
| Blank, C; Dünnwald, T; Gmeiner, G; Schobersberger, W | 1 |
| Jargin, SV | 1 |
| Afanas'ev, VV; Murashko, NK | 1 |
2 review(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Cardiovascular Diseases
| Article | Year |
|---|---|
Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity.
Topics: Animals; Biomarkers; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular Diseases; Humans; Methylhydrazines; Myocardium | 2016 |
Story behind meldonium-from pharmacology to performance enhancement: a narrative review.
Topics: Athletes; Athletic Performance; Cardiovascular Diseases; Carnitine; Doping in Sports; Humans; Metabolic Diseases; Methylhydrazines; Nervous System Diseases | 2017 |
2 trial(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Cardiovascular Diseases
| Article | Year |
|---|---|
[Using meldonium to improve the adaptation of patients with cardiovascular disease to the effects of heat and correction of associated oxidative stress].
Topics: Adaptation, Physiological; Adult; Aged; Antioxidants; Cardiovascular Agents; Cardiovascular Diseases; Drug Monitoring; Female; Hemodynamics; Hot Temperature; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Methylhydrazines; Middle Aged; Oxidative Stress; Quality of Life; Superoxide Dismutase; Treatment Outcome | 2014 |
[The ability to use meldonium as adaptogen in winter in patients with cardiovascular disease].
Topics: Adjuvants, Immunologic; Aged; Carbohydrate Metabolism; Cardiovascular Agents; Cardiovascular Diseases; Cold Temperature; Drug Monitoring; Drug Therapy, Combination; Female; Hemodynamics; Humans; Lipid Metabolism; Male; Methylhydrazines; Middle Aged; Seasons; Treatment Outcome | 2014 |
3 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Cardiovascular Diseases
| Article | Year |
|---|---|
Two-component carnitine monooxygenase from Escherichia coli: functional characterization, inhibition and mutagenesis of the molecular interface.
Topics: Cardiovascular Diseases; Carnitine; Disulfides; Escherichia coli; Flavin Mononucleotide; Humans; Methylamines; Methylhydrazines; Mixed Function Oxygenases; Mutagenesis; Oxidoreductases; Oxygenases; Sulfinic Acids | 2022 |
Meldonium (Mildronate): Primum nоn nocere.
Topics: Adjuvants, Immunologic; Animals; Cardiovascular Agents; Cardiovascular Diseases; Carnitine; Humans; Methylhydrazines; Randomized Controlled Trials as Topic | 2016 |
[Mildronat--treatment of cardio-neurologic pathology in ischemia and hypoxia].
Topics: Cardiovascular Agents; Cardiovascular Diseases; Cerebrovascular Circulation; Cerebrovascular Disorders; Energy Metabolism; Humans; Hypoxia; Ischemia; Methylhydrazines; Randomized Controlled Trials as Topic | 2012 |